161 related articles for article (PubMed ID: 28549419)
1. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
2. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
Sand LG; Scotlandi K; Berghuis D; Snaar-Jagalska BE; Picci P; Schmidt T; Szuhai K; Hogendoorn PC
Eur J Cancer; 2015 Nov; 51(17):2624-33. PubMed ID: 26428435
[TBL] [Abstract][Full Text] [Related]
3. Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.
Buckle T; Kuil J; van den Berg NS; Bunschoten A; Lamb HJ; Yuan H; Josephson L; Jonkers J; Borowsky AD; van Leeuwen FW
PLoS One; 2013; 8(1):e48324. PubMed ID: 23326303
[TBL] [Abstract][Full Text] [Related]
4. High-resolution imaging and single-cell analysis via laser ablation-inductively coupled plasma-mass spectrometry for the determination of membranous receptor expression levels in breast cancer cell lines using receptor-specific hybrid tracers.
Van Acker T; Buckle T; Van Malderen SJM; van Willigen DM; van Unen V; van Leeuwen FWB; Vanhaecke F
Anal Chim Acta; 2019 Oct; 1074():43-53. PubMed ID: 31159938
[TBL] [Abstract][Full Text] [Related]
5. Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.
Krook MA; Nicholls LA; Scannell CA; Chugh R; Thomas DG; Lawlor ER
Mol Cancer Res; 2014 Jun; 12(6):953-64. PubMed ID: 24651452
[TBL] [Abstract][Full Text] [Related]
6. Novel splice variants of CXCR4 identified by transcriptome sequencing.
Sand LG; Jochemsen AG; Beletkaia E; Schmidt T; Hogendoorn PC; Szuhai K
Biochem Biophys Res Commun; 2015 Oct; 466(1):89-94. PubMed ID: 26321665
[TBL] [Abstract][Full Text] [Related]
7. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
8. Peptide-functionalized luminescent iridium complexes for lifetime imaging of CXCR4 expression.
Kuil J; Steunenberg P; Chin PT; Oldenburg J; Jalink K; Velders AH; van Leeuwen FW
Chembiochem; 2011 Aug; 12(12):1897-903. PubMed ID: 21739561
[TBL] [Abstract][Full Text] [Related]
9. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease.
Berghuis D; Schilham MW; Santos SJ; Savola S; Knowles HJ; Dirksen U; Schaefer KL; Vakkila J; Hogendoorn PC; Lankester AC
Clin Sarcoma Res; 2012 Dec; 2(1):24. PubMed ID: 23249693
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.
van den Berg NS; Buckle T; Kuil J; Wesseling J; van Leeuwen FW
Transl Oncol; 2011 Aug; 4(4):234-40. PubMed ID: 21804919
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Imaging Labels: Providing the Link Between Mass Spectrometry-Based Molecular Pathology and Theranostics.
Buckle T; van der Wal S; van Malderen SJ; Müller L; Kuil J; van Unen V; Peters RJ; van Bemmel ME; McDonnell LA; Velders AH; Koning F; Vanhaeke F; van Leeuwen FW
Theranostics; 2017; 7(3):624-633. PubMed ID: 28255355
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.
Oishi S; Masuda R; Evans B; Ueda S; Goto Y; Ohno H; Hirasawa A; Tsujimoto G; Wang Z; Peiper SC; Naito T; Kodama E; Matsuoka M; Fujii N
Chembiochem; 2008 May; 9(7):1154-8. PubMed ID: 18412193
[TBL] [Abstract][Full Text] [Related]
13. A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma.
Krook MA; Hawkins AG; Patel RM; Lucas DR; Van Noord R; Chugh R; Lawlor ER
Oncotarget; 2016 Sep; 7(38):61775-61788. PubMed ID: 27528222
[TBL] [Abstract][Full Text] [Related]
14. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
[TBL] [Abstract][Full Text] [Related]
15. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors.
Hanaoka H; Mukai T; Tamamura H; Mori T; Ishino S; Ogawa K; Iida Y; Doi R; Fujii N; Saji H
Nucl Med Biol; 2006 May; 33(4):489-94. PubMed ID: 16720240
[TBL] [Abstract][Full Text] [Related]
16. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
[TBL] [Abstract][Full Text] [Related]
17. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.
Kuil J; Buckle T; Oldenburg J; Yuan H; Borowsky AD; Josephson L; van Leeuwen FW
Mol Pharm; 2011 Dec; 8(6):2444-53. PubMed ID: 22085282
[TBL] [Abstract][Full Text] [Related]
18. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
19. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
